File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: Safety and tolerance of high intensive focused ultrasound ablation for hepatocellular carcinoma in 100 consecutive patients
  • Basic View
  • Metadata View
  • XML View
TitleSafety and tolerance of high intensive focused ultrasound ablation for hepatocellular carcinoma in 100 consecutive patients
 
AuthorsCheung, TT
Poon, RTP
Lo, CM
Fan, ST
 
KeywordsMedical sciences
Endocrinology
 
Issue Date2011
 
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
 
CitationThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 453-454, abstract PP33-13 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-010-9241-z
 
AbstractHigh intensive focused ultrasound ablation (HIFU) is a novo noninvasive ablation methods for hepatocellular carcinoma (HCC). Emerging evidence has shown that it is effective in the treatment of HCC particularly in patient with poor liver function. Unlike partial hepatectomy or RFA for HCC on patients with cirrhosis, there are no data on the safety limit of HIFU. However, information is vital for the selection of appropriate patients for the procedure. In this study, we analyzed the results of HIFU on HCC patients and determined the lower limit of liver function and other patient’s factors with which HCC patients can tolerate HIFU. METHOD: Preoperative variables of consecutive 100 patients who underwent HIFU for HCC were analyzed to identify the risk factors in HIFU intolerance in terms of morbidity associated with stress-induced complications. RESULTS: 15 patients were in Child Pugh grade B liver cirrhosis and 1 patient was in Pugh Child C liver cirrhosis. 15 patients presented with ascites before treatment. Thirteen (13%) patients developed intolerance to HIFU. Postoperative morbidity was mainly due to skin and subcutaneous injury (n = 9), five patients developed first degree skin burn, one patient developed second degree skin burn and three patients developed third degree skin burn. Two patients developed pneumothorax, one patient developed hyperbilirubinemia and six patients developed other complications. Univariated analysis only showed that age (p = 0.022) is the single independent factor that predict the development of intolerance. CONCLUSIONS: HIFU is generally well tolerated inpatients with cirrhosis. This is a safe method for patients even when TACE is considered risky as a treatment modality. This ablative treatment modality can be used in selected patients with Pugh Child C liver cirrhosis.
 
Descriptionpp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011
 
ISSN1936-0533
2012 Impact Factor: 2.642
2012 SCImago Journal Rankings: 0.775
 
DOIhttp://dx.doi.org/10.1007/s12072-010-9241-z
 
DC FieldValue
dc.contributor.authorCheung, TT
 
dc.contributor.authorPoon, RTP
 
dc.contributor.authorLo, CM
 
dc.contributor.authorFan, ST
 
dc.date.accessioned2011-07-27T02:02:45Z
 
dc.date.available2011-07-27T02:02:45Z
 
dc.date.issued2011
 
dc.description.abstractHigh intensive focused ultrasound ablation (HIFU) is a novo noninvasive ablation methods for hepatocellular carcinoma (HCC). Emerging evidence has shown that it is effective in the treatment of HCC particularly in patient with poor liver function. Unlike partial hepatectomy or RFA for HCC on patients with cirrhosis, there are no data on the safety limit of HIFU. However, information is vital for the selection of appropriate patients for the procedure. In this study, we analyzed the results of HIFU on HCC patients and determined the lower limit of liver function and other patient’s factors with which HCC patients can tolerate HIFU. METHOD: Preoperative variables of consecutive 100 patients who underwent HIFU for HCC were analyzed to identify the risk factors in HIFU intolerance in terms of morbidity associated with stress-induced complications. RESULTS: 15 patients were in Child Pugh grade B liver cirrhosis and 1 patient was in Pugh Child C liver cirrhosis. 15 patients presented with ascites before treatment. Thirteen (13%) patients developed intolerance to HIFU. Postoperative morbidity was mainly due to skin and subcutaneous injury (n = 9), five patients developed first degree skin burn, one patient developed second degree skin burn and three patients developed third degree skin burn. Two patients developed pneumothorax, one patient developed hyperbilirubinemia and six patients developed other complications. Univariated analysis only showed that age (p = 0.022) is the single independent factor that predict the development of intolerance. CONCLUSIONS: HIFU is generally well tolerated inpatients with cirrhosis. This is a safe method for patients even when TACE is considered risky as a treatment modality. This ablative treatment modality can be used in selected patients with Pugh Child C liver cirrhosis.
 
dc.descriptionpp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011
 
dc.description.otherThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 453-454, abstract PP33-13
 
dc.identifier.citationThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 453-454, abstract PP33-13 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-010-9241-z
 
dc.identifier.doihttp://dx.doi.org/10.1007/s12072-010-9241-z
 
dc.identifier.epage454
 
dc.identifier.hkuros188342
 
dc.identifier.issn1936-0533
2012 Impact Factor: 2.642
2012 SCImago Journal Rankings: 0.775
 
dc.identifier.issue1
 
dc.identifier.spage453
 
dc.identifier.urihttp://hdl.handle.net/10722/136096
 
dc.identifier.volume5
 
dc.languageeng
 
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
 
dc.publisher.placeUnited States
 
dc.relation.ispartofHepatology International
 
dc.rightsThe original publication is available at www.springerlink.com
 
dc.subjectMedical sciences
 
dc.subjectEndocrinology
 
dc.titleSafety and tolerance of high intensive focused ultrasound ablation for hepatocellular carcinoma in 100 consecutive patients
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Cheung, TT</contributor.author>
<contributor.author>Poon, RTP</contributor.author>
<contributor.author>Lo, CM</contributor.author>
<contributor.author>Fan, ST</contributor.author>
<date.accessioned>2011-07-27T02:02:45Z</date.accessioned>
<date.available>2011-07-27T02:02:45Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 453-454, abstract PP33-13</identifier.citation>
<identifier.issn>1936-0533</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/136096</identifier.uri>
<description>pp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011</description>
<description.abstract>High intensive focused ultrasound ablation (HIFU) is a novo noninvasive ablation methods for hepatocellular carcinoma (HCC). Emerging evidence has shown that it is effective in the treatment of HCC particularly in patient with poor liver function. Unlike partial hepatectomy or RFA for HCC on patients with cirrhosis, there are no data on the safety limit of HIFU. However, information is vital for the selection of appropriate patients for the procedure. In this study, we analyzed the results of HIFU on HCC patients and determined the lower limit of liver function and other patient&#8217;s factors with which HCC patients can tolerate HIFU. METHOD: Preoperative variables of consecutive 100 patients who underwent HIFU for HCC were analyzed to identify the risk factors in HIFU intolerance in terms of morbidity associated with stress-induced complications. RESULTS: 15 patients were in Child Pugh grade B liver cirrhosis and 1 patient was in Pugh Child C liver cirrhosis. 15 patients presented with ascites before treatment. Thirteen (13%) patients developed intolerance to HIFU. Postoperative morbidity was mainly due to skin and subcutaneous injury (n = 9), five patients developed first degree skin burn, one patient developed second degree skin burn and three patients developed third degree skin burn. Two patients developed pneumothorax, one patient developed hyperbilirubinemia and six patients developed other complications. Univariated analysis only showed that age (p = 0.022) is the single independent factor that predict the development of intolerance. CONCLUSIONS: HIFU is generally well tolerated inpatients with cirrhosis. This is a safe method for patients even when TACE is considered risky as a treatment modality. This ablative treatment modality can be used in selected patients with Pugh Child C liver cirrhosis.</description.abstract>
<language>eng</language>
<publisher>Springer New York LLC. The Journal&apos;s web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0</publisher>
<relation.ispartof>Hepatology International</relation.ispartof>
<rights>The original publication is available at www.springerlink.com</rights>
<subject>Medical sciences</subject>
<subject>Endocrinology</subject>
<title>Safety and tolerance of high intensive focused ultrasound ablation for hepatocellular carcinoma in 100 consecutive patients</title>
<type>Conference_Paper</type>
<identifier.doi>10.1007/s12072-010-9241-z</identifier.doi>
<identifier.hkuros>188342</identifier.hkuros>
<identifier.volume>5</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>453</identifier.spage>
<identifier.epage>454</identifier.epage>
<publisher.place>United States</publisher.place>
<description.other>The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 453-454, abstract PP33-13</description.other>
</item>